In recent times, researchers have identified several oncogenic mutations and have targeted these mutations as an alternative to cancer therapy.
Global TRK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global TRK Inhibitors Market Opportunity Assessment: > USD 2 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 Drugs (Vitrakvi & Rozlytrek)
- Approved TRK Drug Patent, Price & Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
https://www.kuickresearch.com/report-trk-inhibitors-market-size-sales-growth-forecast
In recent times, researchers have identified several oncogenic mutations and have targeted these mutations as an alternative to cancer therapy. Recently, researchers have identified NTRK gene fusions involving NTRK1, NTRK2, or NTRK3 encoding the neurotropin receptors TRKA, TRKB, and TRKC respectively as the oncogenic driver in several adult and pediatric cancers. These receptors have critical role in the development and progression of cancer and hence emerged out to be potential target in cancer management.
To date, two TRK inhibitors have entered the market which has shown robust response in the management of NTRK positive cancers. Lorlatrectinib was the first TRK inhibitor which was approved by FDA in 2018 for the management of NTRK positive solid tumors. The drug is sold under the brand name Vitrakvi and was developed by Loxo Oncology. Later in 2019, Rozlytrek developed by Roche was also approved for the management of NTRK positive solid tumors as well as non-small cell lung cancer. Both these drugs are first generation TRK inhibitor and have shown potent activity against wild-type TRKA, TRKB, and TRKC. Researchers are also evaluating the role of approved TRK inhibitors in other cancer including non-small cell lung cancer, glioblastoma, colorectal cancer, and other hematological malignancies. For instance, Vitrakvi currently present in phase-II for the management of acute leukemia.
Although these drugs have shown promising response, but they are associated with drug resistance which drives the need for the development of next generation TRK inhibitors. For instance, Loxo Oncology has developed LOXO-195 which is highly selective for all three TRK kinases and exhibits potent inhibition of all three. Currently, it is present in phase-I/II clinical trial and is expected to enter the market during forecast period. Apart from this, scientists are also exploring several combinational approaches to overcome the drug resistance with approved TRK inhibitors.
The promising response of TRK inhibitors in short span of time has encouraged pharmaceutical companies to actively invest in this sector. In recent times, pharmaceutical companies have started to embrace a more collaborative way of working as part of a movement to help overcome some of the challenges the industry is facing. For instance in May, 2021 AUM Biosciences entered into collaboration agreement with Handok and CMG Pharmaceutical for the worldwide development, manufacturing, and commercialization rights of CHC2014 which is highly specific and efficacious pan-TRK inhibitor. The other key players working in TRK inhibitor market include AstraZeneca, Pfizer, Bayer, Loxo Oncology, Innocare, Ono Pharmaceutical, and Turning Point Therapeutics.
As per our report findings, the global TRK inhibitor market is expected to surpass US$ 2 Billion by 2026. The market is driven by the rising prevalence of various cancers. Moreover, the increasing awareness regarding the availability of various new therapies to treat cancer is fueling the demand for the TRK inhibitors among the global cancer patients. Furthermore, the rising investments by the biopharmaceutical companies in the development of next generation TRK inhibitors and diagnostic devices are fostering the growth of the market. US is estimate to hold maximum share in the market due to increased prevalence of the cancer, higher healthcare expenditure, increasing awareness regarding the new biopharmaceutical drugs, presence of the world’s top drug manufacturers, and the presence of sophisticated and developed healthcare infrastructure in the region.
The report provides comprehensive analysis on the availability of TRK inhibitors, pricing, dosage, and sales analysis. In addition, deep insights into ongoing clinical trials in global market and key drugs in research and development are also mentioned in the report. On the basis of region, the report has been segmented into US, Europe, Japan, and rest of world whereas by therapeutic indication, it is segmented into lung cancer, breast cancer, colorectal cancer, glioblastoma, and thyroid cancer.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366